Dexcom reports strong Q2 growth and raises full-year guidance on G7 adoption and international expansion

Dexcom (DXCM) posted robust Q2 2026 results with 13.1% revenue growth and nearly 50% operating income increase, driven by adoption of its G7 system and international market expansion. The company also advanced its 'Road to 100' initiative to broaden diabetes coverage. Improved margins, ongoing share buybacks, and a strong balance sheet support Dexcom's growth and capital strategy. Despite a 16% stock price rise nearing intrinsic value, the analyst maintains a Buy rating, reflecting confidence in Dexcom's long-term prospects.